人工授精市场－全球产业规模、份额、趋势、机会及预测（依技术、组件、来源、最终用户、地区及竞争格局划分，2021-2031年）

全球人工授精市场预计将从 2025 年的 30.8 亿美元成长到 2031 年的 46.6 亿美元，复合年增长率为 7.15%。

人工授精是一种专门的辅助生殖技术，它利用仪器将精子注入雌性生殖道，无需自然交配即可实现受精。该市场的主要驱动力是农业领域加速遗传改良的需求，它使生产者能够比自然交配更有效地提高牲畜的生产力和性状品质。此外，严格的生物安全措施也是推动该技术发展的重要因素，因为这种方法显着降低了牲畜间性行为感染传染病的风险。

同时，市场扩张的主要障碍包括对高技能技术人员的需求以及确保受孕成功率所需的高成本低温运输基础设施。这些技术障碍往往会推高营运成本，并限制缺乏健全物流网路的发展中地区的供应。美国国家动物育种者协会 (NAAB) 的报告强调了该行业的最新趋势，报告称，美国牛精液行业到 2024 年的总销售量将达到约 6900 万份，比上一年增长 4%。

市场驱动因素

男性和女性不孕症发病率的上升，尤其是在医疗保健领域，是推动全球人工授精市场扩张的主要因素。这一增长主要源于生活方式的改变和全球生育年龄延迟的趋势，导致人们越来越需要医疗辅助才能怀孕。随着自然受孕率因老龄化和环境因素而下降，人们对辅助生殖技术的依赖性日益增强，使得人工授精成为全球夫妇和非传统家庭的重要服务。为了凸显这项挑战的严峻性，世界卫生组织（世卫组织）于2025年11月发布了一份「不孕症」情况说明书，估计全球约有六分之一的育龄人口在其一生中将面临不孕不育的困扰，这凸显了对有效生殖解决方案的巨大且不断增长的需求。

畜牧业遗传改良和疾病管理的需求是兽医领域的第二大市场驱动因素。生产者越来越多地采用人工授精来传播优良的遗传性状，例如提高饲料转换率和增强抗病能力，这对于满足全球对优质动物蛋白日益增长的需求至关重要。这种做法也能降低自然繁殖带来的生物安全风险，促进畜群健康发展，并实现永续的生产週期。为了佐证遗传改良的商业性价值，Genus plc 在 2025 年 9 月发布的「截至 2025 年 6 月 30 日的年度初步业绩报告」中指出，其牛隻部门的累计营业利润为 1,950 万英镑。此外，Viking Genetics 在 2025 年 4 月发布的「2024 年年度报告」中也反映了更广泛的市场趋势，报告显示，该合作社的总收入达到 3,510 万欧元，主要得益于性别分选精液销量的成长。

市场挑战

对高技能技术人员和先进低温运输基础设施的需求是全球人工授精市场成长的一大障碍。这项辅助生殖技术高度依赖透过持续低温储存和授精过程中的严格操作来维持胚胎的生物活性。物流流程中的任何疏忽或操作人员技能的不足都可能导致受孕率下降，从而大幅增加每次怀孕的成本，并降低生产者的投资报酬率。因此，在缺乏技术培训和稳定能源基础设施的地区，采用这项技术在经济上仍然不切实际。

遗传物质市场价值的上涨加剧了这个财务负担，增加了营运所需的资金。不断上涨的投入成本限制了小型企业和发展中市场的准入，因为它们无法负担先进物流相关的高昂成本。根据美国国家畜牧育种者协会预测，受平均混合精液价格持续上涨的推动，美国精液出口额预计将在2024年增长超过6%，达到创纪录的3.26亿美元。成本上涨的趋势直接阻碍了精液的普及，提高了市场进入的财务门槛。

市场趋势

微流体技术在精子分选领域的应用正在革新临床工作流程，取代了传统的离心技术，后者常导致DNA碎片化。这些先进的设备模拟女性生殖道的天然屏障，分离出具有高活力、高存活率和优异基因组完整性的精子，从而提高人工授精的受孕率。这项技术革新正在推动产业整合，并促使领先的生育机构扩大产品组合。例如，Cooper Surgical在2024年6月发布的通讯协定中宣布收购ZyMot Fertility，并将其微流体精子分选设备纳入其全球产品组合，该新闻稿题为“精子分离技术加入Cooper Surgical的核心生育产品和服务”，凸显了其对先进分选解决方案的商业性关注。

同时，数位生育治疗平台的激增和远端医疗的整合，透过提供克服地理限制的虚拟医疗模式，正在重新定义市场准入。这些平台能够实现远距离诊断、週期追踪以及为家庭人工授精和诊所协调提供后勤支持，从而有效降低了准父母的准入门槛。这种医疗保健的去中心化趋势正在吸引大量投资，以拓展虚拟诊所的服务范围。例如，数位医疗公司Maven Clinic在2024年10月的新闻稿「Maven Clinic宣布完成1.25亿美元F轮资金筹措」中宣布，已筹集1.25亿美元用于拓展其虚拟生育治疗和家庭构建支援服务，这印证了市场对技术主导的远距生育服务的日益依赖。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球人工授精市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依技术（子宫颈内、子宫颈内、阴道内、输卵管内）
  • 依组件分类（人工授精套装、家用人工授精装置、其他）
  • 依来源（配偶人工受孕、捐精）
  • 依最终使用者（医院、生育诊所/中心、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美人工授精市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲人工授精市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区人工授精市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章 中东和非洲人工授精市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲人工授精市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球人工授精市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Ocket Medical plc
• Kitazato Corporation
• Vitrolife AB
• Genea Limited
• Rinovum Women's Health, LLC
• Pride Angel Limited
• FUJIFILM Irvine Scientific, Inc.
• Conceivex, Inc.
• Surelife Pte Ltd.
• Biogenics Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Artificial Insemination Market is projected to expand from a valuation of USD 3.08 Billion in 2025 to USD 4.66 Billion by 2031, reflecting a compound annual growth rate of 7.15%. Defined as a specialized assisted reproductive technology, artificial insemination involves the instrumental delivery of sperm into the female reproductive tract to achieve fertilization without natural mating. The market is predominantly underpinned by the agricultural sector's need for accelerated genetic enhancement, enabling producers to improve herd productivity and trait quality more effectively than natural service methods. Additionally, the stringent requirement for biosecurity measures serves as a key propellant, as this method substantially lowers the risk of transmitting venereal diseases among livestock.

Conversely, a major obstacle hindering widespread market growth is the necessity for highly proficient technicians and costly cold-chain infrastructure to guarantee successful conception rates. This technical hurdle frequently elevates operational expenses and restricts availability in developing areas lacking robust logistics. Highlighting the industry's recent trajectory, the National Association of Animal Breeders reported that in 2024, the U.S. bovine semen industry achieved a total sales volume of nearly 69 million units, marking a 4% rise compared to the prior year.

Market Driver

The rising incidence of male and female infertility serves as a primary driver for the expansion of the Global Artificial Insemination Market, particularly within the human healthcare sector. This growth is substantially fueled by lifestyle shifts and a global trend toward delayed parenthood, which increase the need for medical assistance to realize conception. As natural fertility rates diminish due to aging and environmental influences, dependence on assisted reproductive technologies has deepened, making artificial insemination a vital service for couples and non-traditional families globally. Emphasizing the magnitude of this challenge, the World Health Organization's 'Infertility' fact sheet from November 2025 estimates that roughly one in six individuals of reproductive age worldwide will face infertility during their lifetime, highlighting the critical and expanding demand for effective reproductive solutions.

The need for genetic advancement and disease control in livestock acts as a second major market propeller, driving the veterinary segment. Producers are increasingly utilizing artificial insemination to propagate superior genetic traits, such as improved feed efficiency and disease resistance, which are crucial for satisfying the growing global appetite for high-quality animal protein. This approach also mitigates biosecurity threats linked to natural mating, promoting healthier herds and sustainable production cycles. Validating the commercial significance of these genetic improvements, Genus plc's 'Preliminary Results for the Year Ended 30 June 2025' released in September 2025 noted that its bovine division generated an adjusted operating profit of £19.5 million. Furthermore, illustrating broader market trends, VikingGenetics reported in its '2024 Annual Report Announcement' from April 2025 that the cooperative achieved total revenue of EUR 35.1 million, largely fueled by increasing sales of sexed-sorted semen doses.

Market Challenge

The necessity for highly capable technicians and advanced cold-chain infrastructure poses a significant obstacle to the growth of the global artificial insemination market. This reproductive technology depends heavily on maintaining biological viability through continuous cryogenic storage and exacting handling during the insemination procedure. Any breakdown in this logistical sequence or deficiency in operator skill leads to lower conception rates, effectively raising the cost per pregnancy and eroding the return on investment for producers. Consequently, in areas where technical training and stable energy infrastructure are lacking, implementing this technology remains economically impractical.

This financial burden is further exacerbated by the increasing market value of genetic materials, which raises the capital needed for operations. Elevated input costs restrict access for smaller businesses and developing markets that are unable to afford the premiums linked to sophisticated logistics. According to the National Association of Animal Breeders, the value of U.S. semen exports grew by over 6% in 2024 to reach a record $326 million, driven by a sustained increase in the average blend price. This trend of rising costs directly inhibits widespread adoption by raising the financial barrier required to enter the market.

Market Trends

The integration of microfluidic technologies for sperm sorting is revolutionizing clinical workflows by superseding traditional centrifugation techniques that frequently induce DNA fragmentation. These advanced devices simulate the natural barriers of the female reproductive tract to isolate highly motile, viable sperm with superior genomic integrity, thereby improving fertilization rates in artificial insemination protocols. This technological evolution is fostering significant industry consolidation and portfolio broadening among leading fertility organizations. For instance, CooperSurgical announced in a June 2024 press release titled 'Sperm Separation Technology Adds to CooperSurgical's Leading Fertility Products and Services' that it acquired ZyMot Fertility to incorporate its microfluidic sperm separation devices into their global offerings, highlighting the commercial focus on advanced sorting solutions.

Simultaneously, the proliferation of digital fertility platforms and telehealth integration is redefining market access by providing virtual care models that overcome geographic constraints. These platforms facilitate remote diagnostics, cycle tracking, and logistical assistance for at-home insemination or clinic coordination, effectively reducing entry barriers for prospective parents. This decentralization of reproductive healthcare has drawn considerable investment capital dedicated to expanding virtual clinic frameworks. As evidence of this trend, the digital health company Maven Clinic stated in its October 2024 'Maven Clinic Announces $125 Million Series F Round of Funding' press release that it raised $125 million to broaden its virtual fertility and family-building benefits, confirming the increasing market dependence on technology-driven remote reproductive services.

Key Market Players

• Ocket Medical plc
• Kitazato Corporation
• Vitrolife AB
• Genea Limited
• Rinovum Women's Health, LLC
• Pride Angel Limited
• FUJIFILM Irvine Scientific, Inc.
• Conceivex, Inc.
• Surelife Pte Ltd.
• Biogenics Inc

Report Scope

In this report, the Global Artificial Insemination Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artificial Insemination Market, By Technique

• Intrauterine
• Intracervical
• Intravaginal
• Intratubal

Artificial Insemination Market, By Component

• Insemination Kits
• Home Conception Devices
• Others

Artificial Insemination Market, By Source

• AIH-Husband
• AID-Donor

Artificial Insemination Market, By End User

• Hospitals
• Fertility Clinics & Centers
• Others

Artificial Insemination Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Artificial Insemination Market.

Available Customizations:

Global Artificial Insemination Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Artificial Insemination Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technique (Intrauterine, Intracervical, Intravaginal, Intratubal)
  • 5.2.2. By Component (Insemination Kits, Home Conception Devices, Others)
  • 5.2.3. By Source (AIH-Husband, AID-Donor)
  • 5.2.4. By End User (Hospitals, Fertility Clinics & Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Artificial Insemination Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technique
  • 6.2.2. By Component
  • 6.2.3. By Source
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Artificial Insemination Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technique
      • 6.3.1.2.2. By Component
      • 6.3.1.2.3. By Source
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Artificial Insemination Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technique
      • 6.3.2.2.2. By Component
      • 6.3.2.2.3. By Source
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Artificial Insemination Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technique
      • 6.3.3.2.2. By Component
      • 6.3.3.2.3. By Source
      • 6.3.3.2.4. By End User

7. Europe Artificial Insemination Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technique
  • 7.2.2. By Component
  • 7.2.3. By Source
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Artificial Insemination Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technique
      • 7.3.1.2.2. By Component
      • 7.3.1.2.3. By Source
      • 7.3.1.2.4. By End User
  • 7.3.2. France Artificial Insemination Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technique
      • 7.3.2.2.2. By Component
      • 7.3.2.2.3. By Source
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Artificial Insemination Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technique
      • 7.3.3.2.2. By Component
      • 7.3.3.2.3. By Source
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Artificial Insemination Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technique
      • 7.3.4.2.2. By Component
      • 7.3.4.2.3. By Source
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Artificial Insemination Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technique
      • 7.3.5.2.2. By Component
      • 7.3.5.2.3. By Source
      • 7.3.5.2.4. By End User

8. Asia Pacific Artificial Insemination Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technique
  • 8.2.2. By Component
  • 8.2.3. By Source
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Artificial Insemination Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technique
      • 8.3.1.2.2. By Component
      • 8.3.1.2.3. By Source
      • 8.3.1.2.4. By End User
  • 8.3.2. India Artificial Insemination Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technique
      • 8.3.2.2.2. By Component
      • 8.3.2.2.3. By Source
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Artificial Insemination Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technique
      • 8.3.3.2.2. By Component
      • 8.3.3.2.3. By Source
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Artificial Insemination Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technique
      • 8.3.4.2.2. By Component
      • 8.3.4.2.3. By Source
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Artificial Insemination Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technique
      • 8.3.5.2.2. By Component
      • 8.3.5.2.3. By Source
      • 8.3.5.2.4. By End User

9. Middle East & Africa Artificial Insemination Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technique
  • 9.2.2. By Component
  • 9.2.3. By Source
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Artificial Insemination Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technique
      • 9.3.1.2.2. By Component
      • 9.3.1.2.3. By Source
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Artificial Insemination Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technique
      • 9.3.2.2.2. By Component
      • 9.3.2.2.3. By Source
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Artificial Insemination Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technique
      • 9.3.3.2.2. By Component
      • 9.3.3.2.3. By Source
      • 9.3.3.2.4. By End User

10. South America Artificial Insemination Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technique
  • 10.2.2. By Component
  • 10.2.3. By Source
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Artificial Insemination Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technique
      • 10.3.1.2.2. By Component
      • 10.3.1.2.3. By Source
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Artificial Insemination Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technique
      • 10.3.2.2.2. By Component
      • 10.3.2.2.3. By Source
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Artificial Insemination Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technique
      • 10.3.3.2.2. By Component
      • 10.3.3.2.3. By Source
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Artificial Insemination Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Ocket Medical plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Kitazato Corporation
• 15.3. Vitrolife AB
• 15.4. Genea Limited
• 15.5. Rinovum Women's Health, LLC
• 15.6. Pride Angel Limited
• 15.7. FUJIFILM Irvine Scientific, Inc.
• 15.8. Conceivex, Inc.
• 15.9. Surelife Pte Ltd.
• 15.10. Biogenics Inc

16. Strategic Recommendations

17. About Us & Disclaimer